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Background: Grafts survive despite blood group antigens on the transplant being continu-
ously exposed to antibodies in the blood of recipients in ABO-incompatible kidney trans-
plantation (ABOi KT), owing to the mechanism of accommodation. We analyzed the immu-
nodynamics of soluble ABH antigens in allografts from secretor donors and the influence 
of such immunodynamics on accommodation and subsequent graft survival in ABOi KT. 
Methods: The genotype of a known human β-galactoside α-1,2-fucosyltransferase gene 
(FUT2), which determines soluble ABH antigen secretor status, was established in 32 do-
nors for ABOi KT at the Severance Hospital, from June 2010 to July 2015. Clinical out-
comes of recipients, such as anti-A/B antibody titer change, renal function, and graft sur-
vival, were evaluated. 
Results: Twenty-five donors were secretors (78.1%), and seven were nonsecretors (21.9%). 
The frequency of anti-A/B IgG or IgM antibody titer elevation or reduction post-transplan-
tation was not significantly related to donor secretor status. However, IgM titer was rapidly 
reduced in recipients transplanted from nonsecretor donors (P =0.01), which could be 
explained by the lack of absorption effect of soluble antigens, enhancing the binding of 
antibodies to antigens in the allografts. Interestingly, soluble ABH antigens did not affect 
rejection-free graft survival, which may be due to the nature of β-galactoside α-1,2-fucosyl-
transferase. 
Conclusions: Soluble ABH antigens produced by transplanted kidneys from secretor do-
nors played a role in inducing accommodation within three months of KT through neutral-
ization; however, major graft outcomes were not affected.
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INTRODUCTION
ABO-incompatible kidney transplantation (ABOi KT), a method 
first introduced in the 1970s and widely adopted in the 1990s, 
has expanded the donor pool by increasing the availability of 
transplantable organs and has decreased the waiting period for 
a kidney [1]. Initially, the success of ABOi KT was hindered by 
naturally occurring anti-A/B (anti-A and/or anti-B) antibodies 
that had not been removed from circulation at the time of trans-
plantation; these caused hyperacute rejection in preliminary cases 
[2]. However, the development of potent immunosuppressive 
agents and multiple plasma exchanges allows anti-A/B antibody 
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titers to be reduced prior to transplantation [3], leading to a de-
crease in the rate of acute rejection; from the mid-1980s to to-
day, the rate of acute rejection has decreased to less than 10% 
during the first year following transplantation [4, 5].
During ABOi KT, the pre-existing anti-A/B antibodies target 
the ABH antigens of the transplanted kidney, which are express ed 
on the vascular endothelium, distal convoluted tubules, and col-
lecting tubules [6]. The expression of ABH antigens in human 
tissues differs according to ABO blood group and secretor sta-
tus. Water-soluble ABH antigens are expressed solely in the epi-
thelial cells of the collecting tubules and the calyceal epithelium 
of secretors [7]. In addition, kidney glycolipid antigens have higher 
expression in secretor-positive individuals [8]. The human β-galac-
toside α-1,2-fucosyltransferase gene (FUT2) encodes the β-galac-
toside α-1,2-fucosyltransferase function necessary for the syn-
thesis of ABH antigens in the kidney [9, 10].
Previous studies have suggested that early graft loss after ABOi-
KT may be due to attack of recipient-specific anti-A/B antibod-
ies, including ABH antigens [7, 11]. This phenomenon was later 
referred to as antibody-mediated rejection (ABMR) and defined 
as allograft rejection caused by antibodies directed against do-
nor-specific antigens [12]. The term ‘accommodation’ was intro-
duced in an attempt to explain why some kidney grafts fail while 
others survive incompatible transplantation [13]. Accommoda-
tion refers to the phenomenon in which an antigen-antibody re-
action does not occur, despite the presence of antigens on the 
graft and the existence of antibodies in the blood of the recipient 
[14]. The most compelling mechanism explaining accommoda-
tion is ‘protection’ against the recipients’ antibodies, which in-
volves changes that occur in the graft in response to injury caused 
by antibody binding and complement activation [15]. On the 
basis of several suggested protection mechanisms, we decided 
to investigate the effects of neutralization by ABH substances 
released from the donor kidney in relation to secretor status and 
the influence of this effect on recipient accommodation. To the 
best of our knowledge, this study is the first to examine the rela-
tion between immunodynamics during accommodation and do-
nor secretor status using genotyping during ABOi-KT. 
METHODS
1. Patients
Of the 126 patients who had undergone living donor ABOi KT at 
Severance Hospital, Seoul, Korea from June 2010 to July 2015, 
32 adult recipients with available donor blood samples and neg-
ative pretransplant lymphocyte cross-match tests were enrolled 
in this retrospective study. The study was approved by the Insti-
tutional Review Board (IRB) of Severance Hospital (approval no. 
4-2015-0201) for the retrospective chart reviews and studies of 
existing preserved specimens. The demographics of subjects 
according to the donors’ secretor status were assessed by re-
viewing hospital records and laboratory results (Table 1).
2. Genotyping of the secretor gene
Donor FUT2 (NM_000511.5) genotypes were determined by 
Sanger sequencing using FUT2-specific oligo primers that could 
detect the c.357C>T, c.385A>T, c.428G>A, and fusion gene 
polymorphisms. The functional alleles of FUT2 are Se and Se357, 
whereas se385, se357,385, se428, and sefus have been reported as non-
functional alleles [16]. We designed the oligonucleotide primers 
to amplify 600 bp product for FUT2 as follows: 5´-CAGCGGCTA-
GCGAAGATTCAA-3´ (sense) and 5´-CCAGTCCAGGGCCTGCT-
GTA-3´ (antisense). 
3. Immunosuppressive ABOi-KT regimens 
All patients underwent a pretransplantation conditioning proto-
col consisting of therapeutic plasma exchange (TPE) followed 
by administration of intravenous immunoglobulin (IVIG) (100 
Table 1. Demographic data of recipients
N of recipients
Overall 
(n=32)
From secretor 
donors 
(n=25)
From 
nonsecretor 
donors 
(n=7)
Age at transplant (yr) (median, 
interquartile range)
43.5 (38–52) 47 (40–57) 38 (37–49)
Male/female (male %)  23/9 (71.9) 18/7 (72.0) 5/2 (71.4)
Blood type incompatibilities, n (%) 
   A → B
   A → O
   B → A
   B → O
   AB → O
   AB → A
   AB → B
11 (34.4)
2 (6.3)
8 (25.0)
2 (6.3)
1 (3.1)
4 (12.5)
4 (12.5)
8 (32.0)
2 (8.0)
6 (24.0)
1 (4.0)
1 (4.0)
4 (16.0)
3 (12.0)
3 (42.9)
0 (0.0)
2 (28.6)
1 (14.3)
0 (0.0)
0 (0.0)
1 (14.3)
Range of anti A/B titer before transplant*
Initial titer
   IgG
   IgM
≤2–256
4–512
≤2–128
4–512
2–256
8–128
Baseline titer
   IgG
   IgM
2–16
1–8
2–16
1–8
2–8
2–8
*The titers were transformed to log base 2 and compared with Mann-Whitney 
U test. 
(donor → recipient)
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mg/kg) and immunosuppressants (0.1 mg/day tacrolimus, 1,500 
mg/day mycophenolate, 20 mg/day prednisone, and 375 mg/m2 
rituximab). All patients received pretransplantation conditioning 
prior to the operation. TPE was administered to 27 patients with 
an anti-A/B antibody titer greater than 1:8 using the COBE spec-
tra system (Terumo BCT, Lakewood, CO, USA). One plasma vol-
ume was removed from each patient, and 100% replacement 
was provided by using a 5% albumin solution or AB blood group 
fresh frozen plasma. TPE was performed by using 5% albumin 
solution for the initial sessions, and the last two sessions of TPE 
were carried out with the AB blood group fresh frozen plasma 
(FFP) to prevent bleeding before transplantation. TPE and IVIG 
treatments were conducted every other day before transplanta-
tion until both IgM and IgG titers were no greater than 1:8. Im-
munosuppressive drugs were used before transplantation to pre-
vent graft rejection. Administration of tacrolimus, mycopheno-
late, and prednisone was initiated seven days before transplan-
tation, and rituximab was administered two days before trans-
plantation after performing TPE [3].
4.  Measurement of anti-A/B antibody titers and serum 
creatinine levels
Anti-A/B antibody titers were determined by the tube method, in 
which two-fold serial dilutions of the patients’ serum were tested 
with 3% Affirmagen A/B indicator red cells for IgG and IgM (Or-
tho Diagnostics, Rochester, NY, USA) [17]. After incubation at 
room temperature for 30 min and centrifugation at 973g for 15 
sec, the highest serum dilution ratio that showed 1+ reactivity 
indicated the anti-A/B antibody titers. IgG titers were measured 
by using serum samples treated with 0.01M dithiothreitol solu-
tion (Sigma-Aldrich, St. Louis, MO, USA), while IgM titers were 
determined from untreated samples and read by a single tech-
nician at the same facility to ensure accuracy. Antibody titers 
were evaluated daily following initiation of the conditioning pro-
tocol while preparing for transplantation, and postoperation ti-
ters were determined regularly in patients [3]. One patient, whose 
antibody titers were not evaluated post-transplantation, was ex-
cluded from the titer outcome analysis.
Serum creatinine levels were measured regularly to estimate 
graft function by using the Jaffe method on a Hitachi 7600-210 
autoanalyzer (Hitachi Co. Ltd., Tokyo, Japan) using Sekisui’s Cre-
atinine reagent (Sekisui Diagnostics, Stamford, CT, USA). 
5.  Definition of clinical characteristics and outcome 
parameters
The initial anti-A/B antibody titer was defined as the recipient 
anti-A/B antibody titer prior to any immunomodulatory condition-
ing, such as TPE, IVIG, and immunosuppressant therapy. The 
baseline anti-A/B titer antibody was defined as the recipient anti-
A/B antibody titer immediately prior to transplantation. One pa-
tient exhibiting reduction following postoperative TPE was ex-
cluded from the analysis because the titer could have been af-
fected by the treatment. 
In order to investigate the immunodynamics of soluble ABH 
antigens in allografts from secretor donors that result in accom-
modation, we focused on small fluctuation in anti-A/B antibody 
titers. Titer elevation was defined as one or more Δlog2 titer ele-
vation after transplant from the baseline log2 titer at transplanta-
tion and the time period (days) between at least one Δlog2 titer 
elevation after transplant from the baseline log2 titer at transplan-
tation was counted. Similarly, titer reduction was defined as one 
or more Δlog2 titer reduction after transplant from the baseline 
log2 titer at transplantation, and the time period (days) between 
at least one Δlog2 titer reduction after transplant from the base-
line log2 titer at transplantation was counted. 
6. Diagnosis of graft rejection
Patients with clinically suspected acute rejection exhibiting ei-
ther greater than 20% increase in serum creatinine levels com-
pared with baseline levels or clinical symptoms (e.g., oliguria or 
edema), underwent a biopsy. Rejection or other pathological ﬁnd-
ings were diagnosed according to the Banff 2011 criteria [18]. 
The graft rejection-free survival rate was investigated at two 
time points; that at one month represented the accommodation 
period, and that at one year represented general graft mainte-
nance.
7. Statistical analysis
Statistical analyses were performed by using SPSS software (ver-
sion 23.0; SPSS Inc., Chicago, IL, USA). Medians of non-nor-
mally distributed quantitative values were compared by Mann-
Whitney U tests, and Pearson’s chi-square tests and Fisher’s 
exact tests were used to compare nominal variables. Graft rejec-
tion-free survival rates among patients’ group according to do-
nors’ secretor status were compared using Kaplan-Meier analy-
sis, by log-rank testing. A two-tailed P value of less than 0.05 was 
considered statistically signiﬁcant.
RESULTS
1. Secretor status of the donors 
The secretor statuses of the donors are summarized in Table 2. 
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Table 2. Distribution of secretor genotypes in 32 donors
Estimated phenotype N (%)
Se357/se357,385 Secretor 15 (46.9)
Se/se357,385 6 (18.8)
Se357/Se357 3 (9.4)
Se/Se357 1 (3.1)
se357,385/se357,385 Nonsecretor 7 (21.9)
Total 32 (100.0)
Table 3. Clinical outcomes of patients according to donors’ secretor status
N of recipients*
P value†Overall  
(n=31)
From secretor 
donors (n=24)
From nonsecretor 
donors (n=7)
Anti A/B titer after transplant
Titer elevation, n (%)
   IgG
   IgM
24 (77.4)
22 (71.0)
19 (79.2)
17 (70.8)
(79.2)
(70.8)
5 (71.4)
5 (71.4)
NS
NS
Median days to one Δlog2 titer elevation‡ 
   IgG
   IgM
5
6
3
  9.5
   5.5
6
NS
NS
Titer reduction, n (%)
   IgG
   IgM
4 (12.9)
10 (32.3)
2 (8.3)
6 (25.0)
2 (28.6)
4 (57.1)
NS
NS
Median days to one Δlog2 titer reduction§ 
   IgG
   IgM
2
2
3
3
   1.5
1
NS
0.01
Serum creatinine reduction after transplant
% decrease to minimum level from pre-transplant 84.3±7.0 84.6±6.9 83.4±7.6 NS 
Time to minimum level creatinine reduction (days) 4.7±1.8 4.9±1.8 3.0±0.0 NS
*One patient who received a kidney from a secretor donor was excluded; †Pearson chi-square tests and Fisher’s exact tests were used to compare nominal 
variables, and Mann-Whitney U tests were used for continuous variables to compare clinical outcomes of patients according to donors’ secretor status; ‡Sta-
tistical analyses of IgG and IgM elevations were available in 25 and 23 patients, respectively; §Statistical analyses of IgG and IgM reductions were available in 
4 and 10 patients, respectively.
Abbreviation: NS, not significant.
Fig. 1. The time (days) required for onefold elevation of IgG and IgM 
and reduction of IgG after transplant according to recipient groups. 
The box plot shows the median (bold line), the first quartile (lower 
border of the box) and the third quartile (upper border of the box).
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Individuals carrying the four common genotypes, i.e., Se357/se357,385, 
se357,385/se357,385, Se/se357,385, and Se357/Se357, accounted for 97% 
of the study population. Allele frequencies of the donor secretor 
genotypes, i.e., Se, Se357, se357,385, se428, and sefus, were 0.016, 
0.438, 0.547, 0.000, and 0.000, respectively.
2. Clinical outcomes
1) Anti-A/B antibody titers and renal function after transplantation
As shown in Table 3, of the 31 patients, 24 (77.4%) and 22 (71.0%) 
patients exhibited one or more elevations or reductions in anti-
A/B IgG and IgM antibody titers post-transplantation, respectively, 
compared with the baseline following preconditioning. Reduc-
tions in anti-A/B IgG and IgM antibody titers were only observed 
in four (12.9%) and 10 (32.3%) patients post-transplant, re-
spectively. However, the frequencies of titer elevations and re-
ductions were not significantly different.
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The time (days) required for a one-fold elevation in IgG and 
IgM or reduction in IgG was not significantly different among 
groups; however, the time (days) required for a one-fold reduc-
tion in IgM was significantly different, with IgM titers reduced 
significantly earlier in recipients of nonsecretor donors (RNSD)
(P =0.01; Fig. 1).
All recipients exhibited reduced serum creatinine levels post-
transplantation, usually within the first week. Prior to transplan-
tation, serum creatinine levels were 2.98–15.77 mg/dL in all pa-
tients. Following transplantation, serum creatinine dropped 84.6% 
±6.9% in the recipients of secretor donors (RSD) and 83.4%± 
7.6% in the RNSD group (P =0.713). Minimum creatinine lev-
els were observed at 4.9±1.8 days in the RSD group and at 3.0 
±0.0 days in the RNSD group (P =0.154; Table 3). 
2) Rejection-free graft survival
Biopsies were performed in 13 patients who were clinically sus-
pected of having rejection, including 11 patients in the RSD group 
(44.0%) and two patients in the RNSD group (28.6%). Of the 
patients with biopsy-proven rejection, a mixed form of ABMR 
and T-cell-mediated rejection (TCMR) was observed in two pa-
tients who received kidneys from RSD, while isolated ABMR and 
TCMR were noted in two and three patients, respectively. Inter-
stitial fibrosis and tubular atrophy were observed in only five re-
cipients who had received kidneys from RSD. However, in the 
case of ABMR, the severity was different in two patients; one 
patient in the RNSD group was stage III at day 12 (g1 t0 i1 v3 
cg0 ct0 ci0 cv0 mm0 ah0 ptc2), while the other patient in the 
RSD group was stage I at day 9 (g0 t0 i0 v0 cg0 ct1 ci0 cv0 mm0 
ah0 ptc0).
Fig. 2A and B shows differences in graft rejection-free survival 
within one month and one year post-transplantation between 
the RSD and RNSD groups. The differences in survival rates of 
recipients in the RSD and RNSD groups were not significant at 
both time points (95% confidence interval, 27.8–31.6, P =0.960 
for one month; 286.4–359.8, P =0.943 for one year).
DISCUSSION
The kidney, one of the most vascularized organs, is not immu-
nologically privileged in transplantation because of its endothe-
lium, which expresses donor allo-antigens, and because it is 
readily accessible to circulating antibodies [19]. However, once 
the formidable ABO-incompatibility barrier is overcome by B-
cell depletion and the reduction of circulating isoagglutinins, ac-
commodation plays a central role in graft survival in the face of 
anti-donor (recipient) antibodies [20]. Accommodation may re-
sult from one or more of the three following processes: i) a 
change in antigen, leading to decreased in antibody binding; ii) 
a change in antibodies, reducing their cytotoxicity; and iii) a 
change in the graft, enabling it to resist humoral injury [21]. 
During clinical transplantation accommodation, these processes 
Fig. 2. Rejection-free graft survival within one month post-transplantation (A) and within one year post-transplantation between groups (B). 
The differences in survival rates were not significant at both time points (95% confidence interval, 27.8–31.6, P =0.960 for one month; 
286.4–359.8, P =0.943 for one year).
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could manifest as i) temporal inhibition of glycosyltransferase 
production, resulting in decreased antigenic activity [14]; ii) IgG 
subclass response [22]; or iii) acquired resistance to comple-
ment-mediated lysis [23]. As demonstrated by Tabata et al [24] 
in their xenograft model, accommodation is thought to be preva-
lent post-transplantation, with rapid initiation and subsequent 
persistence for several days. This hypothesis is partially supported 
by findings demonstrating that onset of acute rejection tends to 
occur within one month post-transplantation, with a particularly 
high frequency within the first week [14]. 
Donor secretor status was determined by genotyping the FUT2, 
which is known to be phenotypically associated with ABH sub-
stance secretion [25]. Previous studies have reported a frequency 
of 75.5% secretors and 24.5% nonsecretors in the Korean pop-
ulation [26]. We observed a similar frequency in the donor se-
cretor status in our study: 25 donors (78.1%) were secretors, 
and seven donors (21.9%) were nonsecretors. In addition, we 
did not observe nonsense mutations at c.428G>A or fusion gene 
polymorphisms, consistent with previous findings in the Korean 
population [27]. 
Most patients experienced one or two titer elevations post-trans-
plantation that did not significantly related to donor secretor sta-
tus. However, we observed four cases of IgG titer reduction and 
10 cases of IgM titer reduction, similar to that observed by Taka-
hashi [14] in patients demonstrating good progress. These titer 
reductions may be caused by the dilution effect due to the ex-
pansion of total body volume post-surgery, neutralization by se-
creted antigens, or binding and adsorption by the graft. However, 
since what we measure in the serum is the circulating form of 
IgM post-transplantation, we assumed that allograft binding and 
adsorption may be involved in titer reduction. These findings 
were supported by our observation that titer reduction occurred 
before elevation post-transplantation, indicating that antibodies 
were removed from circulation prior to numerical expansion.
Interestingly, IgM titers showed rapid reductions in recipients 
transplanted with kidneys from RNSD (P =0.01), which could 
be explained by the lack of absorption effect of soluble antigens 
that enhance the binding of antibodies to antigens in the allograft. 
However, the reduction in IgG titers was not significantly differ-
ent between groups, since anti-A/B antibodies are predominantly 
of the IgM class and may be more affected by absorption of sol-
uble ABH than IgG owing to its pentamer structure [28].
The biopsies performed in 13 patients with suspected graft 
rejection showed abnormal findings. ABMR occurs primarily 
because of the antigen-antibody reaction and therefore causes 
injury in renal blood vessels through an indirect pathway. In con-
trast, TCMR is initiated via a direct pathway, resulting in subse-
quent damage to renal tubules [29]. The presence of soluble 
antigens enables possible evasion of antibody binding; however, 
the graft may be endangered by antibody reactions via stimula-
tion of the B-cell response. We predicted that the incidence of 
ABMR might differ between the two groups but that this differ-
ence would not be statistically significant, possibly owing to the 
small number of patients enrolled in the study. However, ABMR 
severity was different in two patients; one patient in the RNSD 
group was stage III, and another patient in the RSD group was 
stage I. Although more evidence is needed, our findings suggest ed 
that the vasculature of grafts from RNSD might be more at risk 
of ABMR by binding of anti-A/B antibodies due to the lack of 
protection by soluble ABH antigens. 
Interestingly, soluble ABH antigens did not affect rejection-free 
graft survival; these findings could be explained by the nature of 
β-galactoside α-1,2-fucosyltransferase, i.e., that some soluble 
substance protects the graft during the initial phase, with a sub-
sequent decrease in activity and production [30, 31]. Indeed, 
during the process of accommodation, protectable soluble ABH 
is altered, which enabled the graft to resist humoral injury; how-
ever, ABH antigenicity has an insignificant role later which leads 
to a decreased antibody binding.
The main limitations of our study were the small population 
size, which hindered our evaluation of the statistical significance 
of the clinical outcomes, and the absence of biopsy protocols, 
which could have provided additional histological information 
regarding the grafts. Furthermore, antibody titers can be quanti-
fied by using advanced methodologies, such as flow cytometry 
or immunoassays, which could have yielded more accurate cor-
relations [32]. However, further studies with larger cohorts are 
required to elucidate the influence of ABH secretor status on 
long-term outcomes. 
In conclusion, the secretor status of donor may have an influ-
ence on early accommodation in patients undergoing ABOi KT. 
However, this could not be supported by anti-A/B antibody ti-
ters, renal function, or graft survival. The minute observations 
on protocol biopsies and quantification of antigens and antibod-
ies with sensitive techniques are needed in larger prospective 
studies of long-term follow-up.
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